| [1] |
Sen M, Shields CL, Honavar SG，et al.Coats disease: An overview of classification, management and outcomes[J]. Indian J Ophthalmol. 2019 Jun；67(6)：763-771.
|
| [2] |
Shields JA, Shields CL, Honavar SG, et al. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture[J]. Am J Ophthalmol, 2001, 131(5): 561-571.
|
| [3] |
Morris B, Foot B, Mulvihill A. A population-based study of Coats disease in the United Kingdom Ⅰ：Epidemiology and clinicalfeatures at diagnosis[J]. Eye(Lond), 2010, 24(12): 1797-1801.
|
| [4] |
Sigler EJ, Randolph JC, Calzada JI, et al. Current management of Coats disease[J]. Surv Ophthalmol, 2014, 59(1): 30-46.
|
| [5] |
Grosso A, Pellegrini M, Cereda MG, et al. Pearls and pitfalls in diagnosis and management of coats disease[J]. Retina, 2015, 35(4): 614-623.
|
| [6] |
Zhang J, Jiang C, Ruan L, et al. Associations of cytokine concentrations in aqueous humour with retinal vascular abnormalities and exudation in Coats′ disease[J]. Acta Ophthalmol, 2019, 97(3): 319-324.
|
| [7] |
Saatci AO, Ayhan Z, Yaman A, et al. A 12-year-old girl with bilateral coats disease and ABCA4 gene mutation[J]. Case Rep Ophthalmol, 2018, 9(2): 375-380.
|
| [8] |
Peene G, Smets E, Legius E, et al. Unilateral Coats′-like disease and an intragenic deletion in the TERC gene: a case report[J]. Ophthalmic Genet, 2018, 39(2): 247-250.
|
| [9] |
Wu JH, Liu JH, Ko YC, et al. Haploinsufficiency of RCBTB1 is associated with Coats disease and familial exudative vitreoretinopathy[J]. Hum Mol Genet, 2016, 25(8): 1637-1647.
|
| [10] |
何璐，陈长征. 成人Coats病诊治进展[J]. 中华眼底病杂志，2018, 34(3)：299-303.
|
| [11] |
杨琼，魏文斌. Coats病的发病机制及治疗[J]. 国际眼科纵览，2015, 39(1)：39-43.
|
| [12] |
Yang X, Wang C, Su G. Recent advances in the diagnosis and treatment of Coats′ disease[J]. Int Ophthalmol, 2019, 39(4): 957-970.
|
| [13] |
Ong SS, Mruthyunjaya P, Stinnett S, et al. Macular features on spectral-domain optical coherence tomography imaging associated with visual acuity in Coats′ disease[J]. Invest Ophthalmol Vis Sci, 2018, 59(7): 3161-3174.
|
| [14] |
Muakkassa NW, de Carlo TE, Choudhry N, et al. Optical coherence tomography angiography findings in Coats′ disease[J]. Ophthalmic Surg Lasers Imaging Retina, 2016, 47(7): 632-635.
|
| [15] |
Warren CC, Young JB, Goldberg MR, et al. Findings in persistent retinopathy of prematurity[J]. Ophthalmic Surg Lasers Imaging Retina, 2018, 49(7): 497-503.
|
| [16] |
Li Y, Peng J, Li J, et al. The characteristics of digenic familial exudative vitreoretinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(11): 2149-2156.
|
| [17] |
Kembhavi SA, Sable N, Vora T, et al. Leukokoria: All That′s White Is Not Retinoblastoma[J]. J Clin Oncol, 2011, 29(19): e586-587.
|
| [18] |
任湘，张明，陆方. 色素失禁症患者眼底及荧光素眼底血管造影影像特征观察[J]. 中华眼底病杂志，2017, 33(5)：534-535.
|
| [19] |
Cebeci Z, Bayraktar Ş,，Ylmaz YC, et al. Evaluation of follow-up and treatment results in Coats′ disease[J]. Turk J Ophthalmol, 2016, 46(5): 226-231.
|
| [20] |
Nucci P, Bandello F, Serafino M, et al. Selective photocoagulation in Coats disease: ten-year follow-up[J]. Eur J Ophthalmol, 12(6): 501-505.
|
| [21] |
Schefler AC, Berrocal AM, Murray TG. Advanced Coats′ disease. Management with repetitive aggressive laser ablation therapy[J]. Retina, 2008, 28(S3): S38-S41.
|
| [22] |
Reichstein DA, Recchia FM. Coats disease and exudative retinopathy[J]. Int Ophthalmol Clin, 2011, 51(1): 93-112.
|
| [23] |
Adam RS, Kertes PJ, Lam WC. Observations on the management of Coats′ disease: less is more[J]. Br J Ophthalmol, 2007, 91(3): 303-306.
|
| [24] |
Othman IS, Moussa M, Bouhaimed M. Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications[J]. Br J Ophthalmol, 2010, 94(5): 606-610.
|
| [25] |
Kaul S, Uparkar M, Mody K, et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats′ disease in children[J]. Indian J Ophthalmol, 2010, 58(1): 76-78.
|
| [26] |
Ramasubramanian A, Shields CL. Bevacizumab for Coats′ disease with exudative retinal detachment and risk of vitreoretinal traction[J]. Br J Ophthalmol, 2012, 96(3): 356-359.
|
| [27] |
Karacorlu M, Hocaoglu M, Sayman Muslubas I, et al. Long-term anatomical and functional outcomes following vitrectomy for advanced coats diseases[J]. Retina, 2017, 37(9): 1757-1764.
|
| [28] |
Kumari R, Saha BC. Bilateral persistent hyperplastic primary vitreous—a rare case report[J]. J Clin Diagn Res, 2017, 11(9): ND01.
|
| [29] |
Galhotra R, Gupta K, Kaur S, et al. Bilateral persistent hyperplastic primary vitreous: A rare entity[J]. Oman J Ophthalmol, 2012, 5(1): 58-60.
|
| [30] |
Chen C, Xiao H, Ding X. Persistent Fetal Vasculature[J]. Asia Pac J Ophthalmol (Phila), 2019, 8(1): 86-95.
|
| [31] |
Manschot WA. Persistent hyperplastic primary vitreous；special reference to preretinal glial tissue as a pathological characteristic and to the development of the primary vitreous[J]. AMA Arch Ophthalmol, 1958, 59(2): 188-203.
|
| [32] |
Shastry BS. Persistent hyperplastic primary vitreous: congenital malformation of the eye[J]. Clin Exp Ophthalmol, 2009, 37(9): 884-890.
|
| [33] |
Aponte EP, Pulido JS, Ellison JW, et al. A novel NDP mutation in an infant with unilateral persistent fetal vasculature and retinal vasculopathy[J]. Ophthalmic Genet, 2009, 30(2): 99-102.
|
| [34] |
Cerón O, Lou PL, Kroll AJ, et al. The vitreo-retinal manifestations of persistent hyperplasic primary vitreous (PHPV) and their management[J]. Int Ophthalmol Clin, 2008, 48(2): 53-62.
|
| [35] |
Zahavi A, Weinberger D, Snir M, et al. Management of severe persistent fetal vasculature: case series and review of the literature[J]. Int Ophthalmol, 2019, 39(3): 579-587.
|
| [36] |
Hu A, Yuan M, Liu F, et al. Ultrasonographic feature of persistent hyperplastic primary vitreous[J]. Eye Sci, 2014, 29(2): 100-103.
|
| [37] |
郑建美，林新霖，魏巍丽. 永存原始玻璃体增生症的临床特征及超声诊断价值[J]. 中外医疗，2017, 36(26)：188-189.
|
| [38] |
De la Huerta I, Mesi O, Murphy B, et al. Spectral domain optical coherence tomography imaging of the macula and vitreomacular interface in persistent fetal vasculature syndrome with posterior involvement[J]. Retina, 2019, 39(3): 581-586.
|
| [39] |
Cheung AY, Kashani AH, Drenser KA. Subretinal peri- papillary neovascularization associated with persistent fetal vasculature[J]. Retin Cases Brief Rep, 2014, 8(1): 83-86.
|
| [40] |
Jeng-Miller KW, Joseph A, Baumal CR. Fluorescein angiography in persistent fetal vasculature[J]. Ophthalmology, 2017, 124(4): 455.
|
| [41] |
|
| [42] |
张征宇，高爱英，鲜军舫，等. 眼球病变的影像学检查与诊断[J]. 中华放射学杂志，2003, 37(2)：181-183.
|
| [43] |
Bosjolie A, Ferrone P. Visual outcome in early vitrectomy for posterior persistent fetal vasculature associated with traction retinal detachment[J]. Retina, 2015, 35(3): 570-576.
|
| [44] |
Li L, Fan DB, Zhao YT, et al. Surgical treatment and visual outcomes of cataract with persistent hyperplastic primary vitreous[J]. Int J Ophthalmol, 2017, 10(3): 391-399.
|
| [45] |
Sudha D, Ganapathy A, Mohan P, et al. Clinical and genetic analysis of Indian patients with NDP-related retinopathies[J]. Int Ophthalmol, 2018, 38(3): 1251-1260.
|
| [46] |
张勤，张琦，赵培泉. NDP基因相关视网膜病变研究[J]. 临床儿科杂志，2013, 31(5)：481-483.
|
| [47] |
梅利斌，黄燕茹，潘乾，等. X连锁隐性遗传诺里病家系的NDP基因突变检测[J]. 中华眼科杂志，2015, 51(5)：360-363.
|
| [48] |
由冰，许可，孙腾洋，等. Norrie病及家族性渗出性玻璃体视网膜病变患者NDP基因突变分析及临床特征[J]. 中华实验眼科杂志，2018, 36(7)：539-543.
|
| [49] |
张天晓，赵秀丽，华芮，等. 我国诺里病家系NDP基因的突变分析[J]. 中华眼科杂志，2012, 48(9)：815-818.
|
| [50] |
杨琼，魏文斌，卢海，等. 22例中国Coats病患儿NDP基因检测分析[J]. 眼科，2016(2)：127-129.
|